Successfully created a Moonfare account
Premium content

Get Access to the Premium Content

Enter your Name and Email and get access to premium content

Name
E-mail Address

Already have an account? Sign in

Premium content

Confirm your Email

Please click on the link that has been just sent to [email] in order to verify your email and proceed to browse investment opportunities

Resend confirmation link
Oops! Something went wrong while submitting the form.

Karo Pharma acquires Pevaryl

Karo Pharma, an EQT VIII portfolio company, has announced the acquisition of the remaining European rights to the Pevaryl brand portfolio from Cilag GmbH International, an affiliate of Johsnon & Johnson.

The acquisition consolidates the full ownership of the Peravyl brand portfolio with Karo Pharma. The portfolio generated net sales of approximately €20M in 2019.

Karo Pharma already commercializes and owns Gyno-Pevaryl , Epi – Pevaryl and Pevaryl in certain European markets.

The brand portfolio is available in more than 20 European countries with €30M in net sales. This acquisition adds scale and scope in new regions such as Italy as well as focus categories of intimate care and foot care.

Source: Karo Pharma

Share:

Join to the Moonfare Platform

Create an Account

Already have an account? Sign in

Invest with Moonfare

Moonfare gives you access to the top 5% of funds we review. Our clients have trusted us to invest over €500 million.

Sign Up